What is the extent of COVID-19 vaccine hesitancy in Bangladesh? : A cross-sectional rapid national survey

Mohammad Ali, M.Phil. ^{1*}, Ahmed Hossain, Ph.D. ²

¹ Department of Physiotherapy and Rehabilitation, Uttara Adhunik Medical College, Uttara Model Town, Dhaka-1230, Bangladesh.

²Department of Public Health, North South University, Basundhara, Dhaka-1229, Bangladesh.

* **Corresponding author:** Mohammad Ali, Department of Physiotherapy and Rehabilitation, Uttara Adhunik Medical College and Hospital, Dhaka-1230, Bangladesh. E-mail: m180002@student.bup.edu.bd, Phone: 88017 15043533.

Emails:

Mohammad Ali: alibup2018@gmail.com

Ahmed Hossain: ahmed.hossain@utoronto.ca

- Word count: Abstract 262, main text (excluding reference and table) 3125.

What is the extent of COVID-19 vaccine hesitancy in Bangladesh? : A cross sectional rapid national survey

Abstract

objectives: To assess COVID-19 vaccine hesitancy in Bangladesh and identify population subgroups with higher odds of vaccine hesitancy.

design: A nationally representative cross-sectional survey was used. Univariate analysis was employed to compute vaccine hesitancy proportions and compare them across groups and multiple logistic regression analyses were performed to compute the adjusted odds ratio.

setting: Bangladesh

participants: A total of 1134 participants from the general population, aged 18 years and above.

outcome measures: Prevalence and predictors of vaccine hesitancy.

results: 32.5% of participants showed COVID-19 vaccine hesitancy. Hesitancy was high among respondents who were males, over age 60, unemployed, from low-income families, from central Bangladesh including Dhaka, living in rented houses, tobacco users, politically affiliated, participants who did not believe in the vaccine's effectiveness for Bangladeshis and those who did not have any physical illnesses in the last year. In the multilevel logistic regression models, respondents who were transgender (AOR= 3.62), married (AOR=1.49), tobacco users (AOR=1.33), those who did not get any physical illnesses in the last year (AOR=1.49), those with political affiliations with opposition parties (AOR= 1.48), those who believed COVID-19 vaccines will not be effective for Bangladeshis (AOR= 3.20), and those who were slightly

concerned (AOR = 2.87) or not concerned at all (AOR = 7.45) about themselves or a family member getting infected with COVID-19 in the next one year were significantly associated with vaccine hesitancy ($p < 0.05$).

conclusions: Given the high prevalence of COVID-19 vaccine hesitancy, it is important to promote evidence-based communication, mass media campaigns, and policy initiatives across Bangladesh to reduce vaccine hesitancy among the Bangladeshi population.

Keywords COVID-19, Bangladesh, Nationwide assessment, Vaccine hesitancy.

Strengths and Limitations of the study

- This study is the first its kind to measure COVID-19 vaccine hesitancy in Bangladesh.
- In this study, randomly selected participants were interviewed face to face, enabling a nearly true representative sample of the Bangladeshi general population.
- This study identified a wide range of sub-groups of the general population with higher odds of COVID-19 vaccine hesitancy relating to their sociodemographic characteristics in Bangladesh; thus, providing baseline evidence for the low and middle-income and low-resourced countries worldwide.
- Traditional media and social media influence on COVID-19 vaccine hesitancy was not measured which is a major limitation of this study.

INTRODUCTION

The first case of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in December 2019 in Wuhan, China. By the first week of February 2021, COVID-19 had infected over 105 million people across 223 countries or territories and caused more than 2.3 million fatalities worldwide [1]. Subsequently, COVID-19 was declared a pandemic by the WHO in March 2020 and many countries began developing COVID-19 vaccines. Two COVID-19 vaccines with 90–95% effectiveness developed by two American pharmaceutical companies were declared at the end of November 2020 [2,3]. Subsequently, many other safe and effective vaccines were also developed and announced by other countries [4–7] and by the end of 2020, 10 vaccines were approved for either full or early use in several countries including the USA, UK, and Canada [8]. Immediately after the approval, the vaccines were rolled out in the respective countries.

However, a vaccination program can be promoted or undermined by factors such as vaccine hesitancy. Vaccine hesitancy refers to delay in acceptance or refusal of vaccination despite the availability of the vaccination service [9]. In 2019, WHO declared vaccine hesitancy as one of the top ten global health threats [10]. After the COVID-19 vaccine started to rollout, besides enthusiasm, news regarding adverse effects of the vaccine experienced by a few vaccine recipients along with conspiracy theories and misinformation on social media have drawn the public's attention worldwide [11]. Hence, puzzling news on the effectiveness of some vaccines by the media has had a negative impact on potential vaccine recipients [12,13]. Moreover, the anxiety and hesitancy is further heightened due to the accelerated pace of vaccine development [14]. Along with contemporary consequences, knowledge and awareness-related issues, vaccine hesitancy can also be determined by religious, cultural, gender, or socio-economic factors [9].

A study indicated that the vaccine willingness rate could range from 55-90% worldwide [15]. However, vaccine willingness and/or hesitancy are subject to change over time [9]. Most of the previous studies were conducted in high-income settings and well before the vaccine was made available. Very little is known about COVID-19 vaccine hesitancy in vaccination programs being run in low-income and middle-income countries' (LMICs) population. As Bangladesh did not participate in any COVID-19 vaccine clinical trial, we hypothesized that due to the novelty of COVID-19 vaccine, there is a lack of awareness of its impact on Bangladeshis. Thus, acceptance and/or hesitancy toward the vaccine might be different compared with other available vaccines in Bangladesh.

The health, economic, and community toll of COVID-19 in Bangladesh are one of the highest among LMICs. By Mid February 2021, in Bangladesh, there were about 0.55 million laboratory-confirmed COVID-19 cases and about 10,000 died from this novel disease [16]. While the COVID-19 vaccine rollout in Bangladesh was inaugurated on 27 January 2021 targeting to immunize 138 million people [17], very little is known about COVID-19 vaccine hesitancy and/or willingness among this cohort. The government, public health officials, and advocates must be prepared to address hesitancy to reach their target and build vaccine literacy among potential recipients. Thus, our study aimed (1) to conduct a rapid national assessment of COVID-19 vaccine hesitancy in Bangladesh, and (2) to identify population subgroups with higher odds of vaccine hesitancy.

METHODS

Design and participants

In a cross-sectional study conducted in Bangladesh from 18 to 31 January 2021, male, female, and transgender persons aged 18 years and above were interviewed using a previously used, valid, and reliable vaccine hesitancy questionnaire [18]. To calculate sample size, a margin of error of 5%, a confidence level of 95%, a response distribution of 50% were used to target a 138 million population and secure a minimum sample size of 1067 [19,20]. Therefore, like a similar Asian study, our sample consisted of 1134 respondents [21].

The questionnaire

The questionnaire comprised of two parts. In the first part, participants were asked questions regarding vaccine hesitancy and COVID-19 threat. First, participants were asked about the likelihood of getting a vaccine. The dependent variable and a key outcome of the study (i.e., vaccine hesitancy) were measured through the question: “If a vaccine that would prevent coronavirus infection was available, how likely is it that you would get the vaccine or shot.” The response options for this question were “Very likely,” “somewhat likely,” “not likely,” “definitely not.” Second, participants were asked two questions regarding the perceived COVID-19 threat: (1) “How likely is it that you or a family member could get infected with coronavirus in the next one year?” with response options: “very likely,” “somewhat likely,” “not likely,” and “definitely not.” (2) “How concerned are you that you or a family member could get infected with coronavirus in the next one year?” with response options: “very concerned,” “concerned,” “slightly concerned,” and “not concerned at all.”

The second part of the questionnaire comprised of a wide range of sociodemographic questions. A set of structured questions assessed participants’ gender, age, religion, marital status, education, employment status, monthly household income in Bangladeshi taka (BDT), permanent address, and region of residence in Bangladesh (north, south, and central zone

including Dhaka), current residence type (Own/rented/hostel or mess), tobacco use and political affiliation. Participants were also asked about the presence of children or older people at home, whether they had any physical illnesses in the last year, whether they had a chronic disease diagnosis (hypertension, diabetes, asthma, etc.), and whether they were regular religious practitioners. These questions had to be answered using the dichotomous option (yes/no). In additions, participants were also asked two more COVID-19 vaccine-related questions: “Do you think the COVID-19 vaccine will be effective among Bangladeshis (no/yes/skeptical), and “Which developers’ vaccine would you prefer to take (American, British, Chinese, Russian, Indian, I have no idea regarding this).

Patient and public involvement

Participants or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Data analysis

Descriptive statistics were computed to describe the demographic characteristics of the study participants. Chi-Square tests were used to compute vaccine hesitancy proportions and draw comparisons across groups. Responses were compared for various sociodemographic characteristics by dichotomizing the variable as either a positive (very likely and somewhat likely) or a negative (not likely and definitely not) attitude toward COVID-19 vaccine, indicating the extent of vaccine hesitancy. To compute adjusted odds ratios (AOR) with a 95% confidence interval, multiple logistic regression analyses were performed with vaccine hesitancy as a dependent variable and sociodemographic characteristics and perceived COVID-19 threat as predictor variables for vaccine hesitancy. To ensure the models adequately fit the data, Hosmer-

Lemeshow goodness-of-fit tests were used. The significance level was set at <0.05 and SPSS version 22.0 (IBM Corp.) was used for data analyses.

RESULTS

Descriptive statistics analyses

Table 1 shows sociodemographic characteristics, COVID-19 threat, and vaccine hesitancy of a total of 1134 Bangladeshis who participated in this study. The mean age of the participants was 32.05 (SD $\pm$ 11.72). The majority of the study participants were: male (59.2%), aged 26-40 (40.7%), Muslim (93.2%), married (52.7%), held a bachelor's degree (31.4%), full-time employees (28.7%), persons with a monthly household income $\geq$ 30,000 BDT (44.9%), from the central zone including Dhaka of Bangladesh (60%), living in their own house (46.3%), tobacco non-users (70.2%), those who did not get physical illnesses (57.3%) and had no political affiliation (56.5%). Regarding the question on the likelihood of getting a COVID-19 vaccine, the responses were: "very likely" (34.2%), "somewhat likely" (53.6%), "not likely" (7.3%), and "definitely not" (5.9%). In addition, **Figure 1** represents day-to-day fluctuation of vaccine hesitancy.

Univariate analysis

Statistically significant differences in vaccine hesitancy were found based on sociodemographic characteristics with the highest prevalence of COVID-19 vaccine hesitancy among males, persons aged over 60, businesspeople and unemployed persons, those with a monthly household income below 15 thousand BDT, living in the central zone, living in a rented house, tobacco users, those who did not face physical illness in the last year, had political affiliations with the

opposition parties, did not believe in COVID-19 vaccine effectiveness among Bangladeshis, and had no knowledge on vaccine developers (**Table 1**).

Furthermore, participants who were not likely to believe that they or a family member could be infected with COVID-19 in the next one year and those who were not concerned at all about themselves or a family member getting COVID-19 infection in the next one year had the highest rates of COVID-19 vaccine hesitancy.

Multiple logistic regression analysis

Table 2. presents predictors of COVID-19 vaccine hesitancy. A multiple regression analysis was conducted to examine predictors of COVID-19 vaccine hesitancy by including factors found to be significantly associated with vaccine hesitancy in the univariate analysis. In this multiple regression model, groups with statistically significantly higher odds of vaccine hesitancy were: transgender persons (AOR= 3.62, 95% CI= 1.177-11.251), married persons (AOR=1.49, CI= 1.047-2.106), tobacco users (AOR=1.33, CI= 1.018-1.745), participants who did not get physical illnesses in the last year (AOR=1.49, CI= 1.134-1.949), those with political affiliations with opposition parties (AOR= 1.48, CI= 1.025-2.134), those who did not believe in COVID-19 vaccines effectiveness for Bangladeshis (AOR= 3.20, CI= 2.079-4.925), and those who were slightly concerned (AOR = 2.87, CI= 1.744-4.721) or not concerned at all (AOR = 7.45, CI= 4.768-11.643) about themselves or a family member getting infected with COVID-19 in the next one year. Likewise, compared with participants who believed it was very likely that they or their family members could get infected with COVID-19 in the next one year, and those who thought such an occurrence would be not likely (AOR = 1.88, CI= 1.109-3.172) had significantly higher odds of vaccine hesitancy. Nonetheless, female participants (AOR= 0.70, CI= 0.537-0.928), students (AOR = 0.60, CI= 0.379-0.966) and those who preferred to take the British (AOR=

0.48, CI= 0.324-0.725), Chinese (AOR=0.44, CI= 0.245-0.807), Russian (AOR= 0.42, CI= 0.222-0.825) or Indian (AOR= 0.33, 0.143-0.774) vaccine had statistically significantly lower odds of vaccine hesitancy.

DISCUSSION

More than one-third of the participants (32.5%) reported vaccine hesitancy in the present comprehensive national study. Analysis of daily data suggested that vaccine hesitancy varied from 18% to 72% in Bangladesh. Moreover, our study identified that predictors of COVID-19 vaccine hesitancy among Bangladeshis are gender, marital status, employment status, tobacco use, physical illness history, political affiliation, faith in vaccine effectiveness among Bangladeshis, vaccine preference, and perceived COVID-19 threat.

This is the first study to measure COVID-19 vaccine hesitancy in Bangladesh; thus, little is known about previous hesitancy rate. However, a June 2020 global survey suggested that more than 80% of participants from China, Korea, and Singapore are very or somewhat likely to receive the COVID-19 vaccine [15]. Another study in September 2020 in Japan found 65% willingness toward the COVID-19 vaccine among participants [21]. However, a January 2021 survey in India suggested that 60% of polled Indians showed hesitancy (40% willingness) towards receiving COVID-19 vaccines [22].

We found higher vaccine hesitancy among male, older, married, and transgender participants. In the final model, women show significantly lower odds of vaccine hesitancy. In agreement with our findings, a global study observed lower odds of vaccine willingness among male participants [15]; however, women in Japan demonstrated very high vaccine hesitancy compared with men

[21]. American women also showed lower willingness toward the COVID-19 vaccine [23].

Nonetheless, an early study suggested that Bangladeshi women's better knowledge, attitude, and practice toward COVID-19 could be the reasons for their lower vaccine hesitancy [24]. An additional regional study is required to determine the gender-based difference in vaccine hesitancy. Unlike other studies, we found higher vaccine hesitancy among older people than younger. This also can be explained by an earlier study that showed lack of sufficient COVID-19-related knowledge among the older population of Bangladesh [24]. Socio-cultural and religious beliefs related to preexisting vaccine hesitancy among the older population could also be another cause of higher vaccine hesitancy. Additionally, results regarding the married population are incorporated with age; therefore, results need to be interpreted by looking at marital status and age together. Furthermore, we found statistically significant higher odds of vaccine hesitancy among the gender minority, that is, the transgender population. Previous research suggested that vaccine hesitancy is universally higher among gender minorities due to limited access and interaction with healthcare professionals, historical biomedical and healthcare-related mistrust, cost-related concerns, lack of belief in the scientific enterprise of medicine and public health, lack of awareness, and education [25].

Unemployment, an education level lower than or equal to high school, and a household monthly income less than 15,000 BDT were associated with a higher likelihood of reporting hesitancy toward COVID-19 vaccine in Bangladesh. In line with our findings, a global study also suggested that participants with lower education and income were less likely to get the COVID-19 vaccine [15]. Moreover, unemployed participants, and participants with a low level of education in the U.S. and Saudi Arabia showed higher vaccine hesitancy [23,26]. In contrast, other studies found that unemployed participants were more likely to accept the COVID-19

vaccine [20, 29]. It could be possible that in some regions, unemployed persons would like to return to work and employment and the vaccine could facilitate this return.

A unique finding of this study was that a high portion of tobacco users showed hesitancy to receive the COVID-19 vaccine. Statistically significantly high odds of vaccine hesitancy (AOR= 1.33) among tobacco users were found in the regression analysis. Universally, tobacco users (including smokers) are known to have unhealthy life practices. Further, a systematic review and meta-analysis concluded that current and previous smoking is clearly associated with severe COVID-19 outcomes [28]. Another systematic review suggested that tobacco use was significantly associated with a higher rate of mortality among COVID-19 patients [29]. So far, there have been discussions on prioritization of vaccination (e.g., for front liners). However, very little vaccination planning has been done for the most vulnerable populations who continue to remain susceptible to COVID-19 outcomes (i.e., a greater number of deaths and severe infections). Our findings would help identify these sub-groups. In contrast, we found high odds (AOR= 1.48) among those who did not have physical illnesses throughout the last year. However, previous evidence suggested that healthier persons can also be infected by COVID-19 and that the outcomes are unpredictable. Policymakers should target these subgroups when planning vaccine literacy for potential vaccine-recipients.

Interestingly, we found statically significantly higher vaccine hesitancy among politically affiliated (either affiliated with ruling parties or oppositions) participants compared with those who described themselves as neutral. However, regression analysis suggested that those who were affiliated with opposition parties had higher odds (AOR= 1.48). A systematic review and meta-analysis found a range of trust relationships with vaccine hesitancy in LMICs; for example,

trust in healthcare professionals, the health system, the government, and friends and family members [30].

It is reported that the effectiveness of vaccines varies from race to race and country to country [31]. However, there was no human clinical trial of any COVID-19 vaccine in Bangladesh. In our study participants were asked whether they believed the vaccines will be effective for Bangladeshi. Those who answered “No” and remained “skeptical” showed a higher rate of vaccine hesitancy. However, this finding is similar to the findings of a study conducted in another country [32]. Finally, our study revealed very high odds of hesitancy (AOR= 7.45) among those who were not concerned about being infected by COVID-19. In support of our findings, a systematic review confirmed that people’s perceived risk of infection is one of the strongest predictors of pandemic vaccine acceptance and/or hesitancy [33].

This study result may have influenced by several limitations. Firstly, it is a cross-sectional study, and portrays a depiction of the community response at the climacteric of the study. Nonetheless, vaccine hesitancy is complex in disposition and adherence-specific, varying over time, location, and perceived behavioral nature of the community [33–35]. Secondly, social and traditional media influence are one of the major predictors of pandemic vaccine hesitancy and/or acceptance [36]. In our study, we did not examine the impact of media and this might have confounded the results. Additional research is warranted to address this issue. Despite these limitations, our study provides baseline evidence for the LMICs regarding COVID-19 vaccine hesitancy. Furthermore, our study identifies many sub-groups of the general population that must be considered during vaccine hesitancy discussions. Finally, data collected by interviewing randomly selected participants from the north, south, and central zone including Dhaka would have given a better,

nearly true representative of the population of Bangladesh in the sample which would have made the study results more plausible.

Conclusion

The present rapid community-based study on COVID-19 vaccine hesitancy in Bangladesh found that more than one-third (32.5%) of the respondents were hesitant about getting vaccinated.

Differences in vaccine hesitancy were based on sociodemographic characteristics, health, and behavior of participants such as gender, age, marital status, income, employment status, tobacco use, history of illness, place of residence, and political affiliation. Further, faith in vaccine effectiveness in Bangladesh and perceived COVID-19 threat were strong predictors of COVID-19 vaccine hesitancy. Various contributing factors to vaccine hesitancy such as preexisting indecisiveness, cultural and religious views, lack of belief in the scientific enterprise of medicine and public health especially among the older population, and lower levels of awareness were identified. Further research is warranted to comprehend the complicated interplay of a variety of individual and social characteristics that influence vaccine hesitancy to ensure extensive coverage of COVID-19 vaccines. Evidence-based educational and policy-level interventions must be implemented to address these problems and promote COVID-19 immunization programs. The rates of willingness are subject to change with the suitability of the vaccines, but frequent and ambivalent effects of vaccines may reduce those rates. The uptake of COVID-19 vaccines can be increased once the factors identified in this study are properly addressed and the long-term positive effects of the vaccines are clarified.

Acknowledgments

Both the authors acknowledge the participants for providing us the information to conduct the study.

Competing interests

The authors declare that they have no competing interests.

Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Data sharing statement

Data will be available from the corresponding author upon reasonable request.

Author contributions

MA participated in study conception, design and coordination of the manuscript. MA also performed the statistical analysis and draft the manuscript. AH reviewed the manuscript and helped to draft the manuscript. Both the authors approved the final manuscript.

Ethical consideration:

Formal ethical approval was taken from the Ethical Review Committee (ERC) of Uttara Adhunik Medical College and Hospital. Prospective observational trial registration has been obtained from the World Health Organization (WHO) endorsed Clinical Trial Registry- India:

CTRI/2021/01/030546. Furthermore, we conducted the study strictly following the STROBE guideline [37]. All the invited participants were required to give informed consent for participation and collection and analysis of their data.

References

1. World Health Organization. Weekly Operational Update on COVID-19. World Heal Organ [Internet]. 2021;(February):1–10. Available from: <https://www.who.int/publications/m/item/weekly-update-on-covid-19---16-october-2020>
2. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med [Internet]. 2020 Dec 31 [cited 2021 Jan 29];383(27):2603–15. Available from: <https://pubmed.ncbi.nlm.nih.gov/33301246/>
3. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med [Internet]. 2020 Dec 30 [cited 2021 Jan 29];NEJMoa2035389. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2035389>
4. Logunov DY, Dolzhikova I V, Shcheblyakov D V, Tukhvatulin AI, Zubkova O V, Dzharullaeva AS, et al. Articles Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet [Internet]. 2021 [cited 2021 Feb 2];0(0). Available from: <https://doi.org/10.1016/S0140-6736>
5. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet [Internet]. 2021 Jan 9 [cited 2021 Jan 29];397(10269):99–111. Available from: <https://doi.org/10.1016/>
6. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis [Internet]. 2021 Feb 1 [cited 2021 Jan 29];21(2):181–92. Available from: www.thelancet.com/infection
7. Caddy S. Russian SARS-CoV-2 vaccine. BMJ [Internet]. 2020 Aug 24 [cited 2021 Jan 29];370:m3270. Available from: <http://dx.doi.org/10.1136/bmj.m3270>
8. How Eight Covid-19 Vaccines Work - The New York Times [Internet]. [cited 2021 Jan 29]. Available from: https://www.nytimes.com/interactive/2021/health/how-covid-19-vaccines-work.html?name=style-coronavirus-vaccines®ion=TOP_BANNER&block=storyline_menu_recirc&action=click&pgtype=Interactive&impression_id=512adde2-6258-11eb-9e5c-17bd043bd909&variant=1_Show
9. MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. Vaccine [Internet]. 2015 Aug 14 [cited 2021 Jan 16];33(34):4161–4. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0264410X15005009>

10. Aranda S. Ten threats to global health in 2019 [Internet]. World Health Organisation (WHO). 2019 [cited 2021 Jan 30]. p. 1–18. Available from: <https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019>
11. Beckett L. Misinformation “superspreaders”: Covid vaccine falsehoods still thriving on Facebook and Instagram. The Guardian [Internet]. 2021 [cited 2021 Jan 31]; Available from: <https://www.theguardian.com/world/2021/jan/06/facebook-instagram-urged-fight-deluge-anti-covid-vaccine-falsehoods>
12. Covid: France restricts AstraZeneca vaccine to under-65s - BBC News [Internet]. BBC News. 2021 [cited 2021 Feb 2]. Available from: <https://www.bbc.com/news/world-europe-55901957>
13. UK defends Oxford vaccine as Germany advises against use on over-65s | World news | The Guardian [Internet]. [cited 2021 Jan 31]. Available from: <https://www.theguardian.com/world/2021/jan/28/germany-recommends-oxford-astrazeneca-covid-vaccine-not-used-over-65s>
14. Fadda M, Albanese E, Suggs LS. When a COVID-19 vaccine is ready, will we all be ready for it? Int J Public Health [Internet]. 2020 Jul 11 [cited 2021 Jan 31];65(6):711–2. Available from: <https://doi.org/10.1007/s00038-020-01404-4>
15. Lazarus J V., Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med [Internet]. 2020 Oct 20 [cited 2021 Jan 16];1–4. Available from: <https://doi.org/10.1038/s41591-020-1124-9>
16. World Health Organization. WHO Coronavirus Disease (COVID-19) Report [Internet]. World Health Organization. 2021 [cited 2021 Jan 29]. Available from: <https://covid19.who.int/>
17. Covid-19 vaccination across Bangladesh to start from Feb 7 | Dhaka Tribune [Internet]. [cited 2021 Jan 31]. Available from: <https://www.dhakatribune.com/health/coronavirus/2021/01/26/health-minister-vaccination-to-start-from-feb-7>
18. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ. COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment. J Community Health [Internet]. 2021 Jan 3 [cited 2021 Jan 14];1–8. Available from: <https://doi.org/10.1007/s10900-020-00958-x>
19. Taherdoost H. Determining sample size; How to calculate survey sample size. Int J Econ Manag Syst [Internet]. 2017;2(2):237–9. Available from: <http://www.iaras.org/iaras/journals/ijems>
20. James E, Joe W, Chadwick C. Organizational research□: Determining appropriate sample size in survey research. Inf Technol Learn Perform J. 2001;19(1):43–50.
21. Yoda T, Katsuyama H. Willingness to Receive COVID-19 Vaccination in Japan. Vaccines [Internet]. 2021 Jan 14 [cited 2021 Jan 16];9(1):48. Available from: <https://www.mdpi.com/2076-393X/9/1/48>
22. Coronavirus update February, 2021 - The Hindu [Internet]. The Hindu. 2021 [cited 2021

- Feb 7]. Available from: <https://www.thehindu.com/news/national/coronavirus-live-updates-february-4-2021/article33745821.ece>
23. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. *EClinicalMedicine* [Internet]. 2020 Sep [cited 2021 Jan 14];26:100495. Available from: <https://doi.org/10.1016/j.eclinm.2020.100495>
24. Ali M, Uddin Z, Banik PC, Hegazy FA, Zaman S, Ambia ASM, et al. Knowledge, attitude, practice and fear of COVID-19: A cross-cultural study. *medRxiv* [Internet]. 2020 May 26 [cited 2020 Aug 11];26(5):2020.05.26.20113233. Available from: <https://www.medrxiv.org/content/10.1101/2020.05.26.20113233v1>
25. Owen-Smith AA, Woodyatt C, Sineath RC, Hunkeler EM, Barnwell LT, Graham A, et al. Perceptions of Barriers to and Facilitators of Participation in Health Research Among Transgender People. *Transgender Heal* [Internet]. 2016 Jan 1 [cited 2021 Feb 4];1(1):187–96. Available from: <http://www.liebertpub.com/doi/10.1089/trgh.2016.0023>
26. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. *J Multidiscip Healthc* [Internet]. 2020 Nov 20 [cited 2021 Feb 5];Volume 13:1657–63. Available from: <https://www.dovepress.com/determinants-of-covid-19-vaccine-acceptance-in-saudi-arabia-a-web-base-peer-reviewed-article-JMDH>
27. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrahi M, Zigron A, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol* [Internet]. 2020 Aug 1 [cited 2021 Feb 5];35(8):775–9. Available from: <https://doi.org/10.1007/s10654-020-00671-y>
28. Gülsen A, Yigitbas BA, Uslu B, Drömann D, Kilinc O. The Effect of Smoking on COVID-19 Symptom Severity: Systematic Review and Meta-Analysis. *Pulm Med* [Internet]. 2020 Sep 9 [cited 2021 Feb 5];2020:1–11. Available from: <https://doi.org/10.1155/2020/7590207>
29. Salah HM, Sharma T, Mehta J. Smoking Doubles the Mortality Risk in COVID-19: A Meta-Analysis of Recent Reports and Potential Mechanisms. *Cureus* [Internet]. 2020 Oct 7 [cited 2021 Feb 5];12(10). Available from: <https://www.cureus.com/articles/39552-smoking-doubles-the-mortality-risk-in-covid-19-a-meta-analysis-of-recent-reports-and-potential-mechanisms>
30. Larson HJ, Clarke RM, Jarrett C, Eckersberger E, Levine Z, Schulz WS, et al. Measuring trust in vaccination: A systematic review. *Hum Vaccin Immunother* [Internet]. 2018 Jul 3 [cited 2021 Feb 5];14(7):1599–609. Available from: <https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1459252>
31. Hernandez D. Pfizer Covid-19 Vaccine Works Against Mutations Found in U.K, South Africa Variants, Lab Study Finds - WSJ [Internet]. *The Wall Street Journal*. 2021 [cited 2021 Feb 5]. Available from: <https://www.wsj.com/articles/pfizer-covid-19-vaccine-works-against-mutations-found-in-u-k-south-africa-variants-lab-study-finds-11611802559>
32. Attwell K, Lake J, Sneddon J, Gerrans P, Blyth C, Lee J. Converting the maybes: Crucial for a successful COVID-19 vaccination strategy. *PLoS One* [Internet]. 2021 [cited 2021

- Jan 24];16(1):e0245907. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33471821>
33. Wilson K, Nguyen, Holdt Henningsen, Brehaut, Hoe. Acceptance of a pandemic influenza vaccine: a systematic review of surveys of the general public. *Infect Drug Resist* [Internet]. 2011 Oct 20 [cited 2021 Feb 5];4(1):197. Available from: <http://www.dovepress.com/acceptance-of-a-pandemic-influenza-vaccine-a-systematic-review-of-surv-peer-reviewed-article-IDR>
 34. Xiao X, Wong RM. Vaccine hesitancy and perceived behavioral control: A meta-analysis. *Vaccine* [Internet]. 2020 Jul 14 [cited 2021 Feb 5];38(33):5131–8. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0264410X20305934>
 35. Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007-2012. Vol. 32, *Vaccine*. Elsevier BV; 2014. p. 2150–9.
 36. Puri N, Coomes EA, Haghbayan H, Gunaratne K. Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases. *Hum Vaccines Immunother* [Internet]. 2020 Nov 1 [cited 2021 Jan 16];16(11):1–8. Available from: <https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1780846>
 37. Vandembroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. *PLoS Med* | www [Internet]. 2007 [cited 2020 Mar 17];4. Available from: <http://www.epidem.com/>

Table 1 Univariate analysis- Sociodemographic characteristics, COVID-19 threat, and vaccine hesitancy

Variables	Total Sample n (%)	Likelihood of getting COVID-19 Vaccine		p-value
		Not likely/definitely not n (%)	Very likely/somewhat-likely n (%)	
All participants	1134 (100%)	369 (32.5)	765 (67.5)	-
<i>Gender</i>				0.003
Transgender	14 (1.2)	9 (64.3)	5 (35.7)	
Female	449 (39.6)	127 (28.3)	322 (71.7)	
Male	671 (59.2)	233 (34.7)	438 (65.3)	
<i>Age group</i>				0.009
18-25	442 (39.0)	122 (27.6)	320 (72.4)	
26-40	461 (40.7)	174 (37.7)	287 (62.3)	
41-60	200 (17.6)	61 (30.5)	139 (69.5)	
≥ 61	31 (2.7)	12 (38.7)	19 (61.3)	
<i>Religion</i>				0.442
Muslim	1057 (93.2)	349 (33.0)	708 (67.0)	
Hindu	61 (5.4)	16 (26.2)	45 (73.8)	
Cristian and Buddhist	16 (1.4)	4 (25.0)	12 (75.0)	
<i>Marital status</i>				0.039
Unmarried	495 (43.6)	141 (28.5)	353 (71.5)	
Married	598 (52.7)	214 (35.8)	384 (64.2)	
Divorce/Widow	42 (3.7)	14 (33.3)	28 (66.7)	
<i>Children at home</i>				0.950
No	481 (42.4)	157 (32.6)	324 (67.4)	
Yes	653 (57.6)	212 (32.5)	441 (67.5)	
<i>Aged people at home</i>				0.224
No	396 (34.9)	138 (34.8)	258 (65.2)	
Yes	738 (65.1)	231 (31.3)	507 (68.7)	
<i>Education</i>				0.268
≤ High school	264 (23.3)	98 (37.1)	166 (62.9)	
College education	309 (27.2)	92 (29.8)	217 (70.2)	
Bachelor's degree	356 (31.4)	111 (31.2)	245 (68.8)	
≥ Master's degree	205 (18.1)	68 (33.2)	137 (66.8)	
<i>Employment status</i>				0.013
Full-time employee	326 (28.7)	109 (33.4)	217 (66.6)	
Part-time employee	73 (6.4)	23 (31.5)	50 (68.5)	
Business	169 (14.9)	66 (39.1)	103 (60.9)	
Unemployed	88 (7.8)	35 (39.8)	53 (60.2)	
Home maker	171 (15.1)	60 (35.1)	111 (64.9)	
Student	307 (27.1)	76 (24.8)	231 (75.2)	
<i>Monthly household income</i>				0.042
<15,000	239 (21.1)	78 (32.6)	161 (67.4)	
15,000-30,000	386 (34.0)	108 (28.0)	278 (72.0)	
≥ 30,000	509 (44.9)	183 (36.0)	326 (64.0)	
<i>Family type</i>				0.205
Nuclear	715 (63.1)	223 (31.2)	492 (68.8)	
Joint	419 (36.9)	146 (34.8)	273 (65.2)	

<i>Permanent address</i>				0.533
Rural	637 (56.2)	216 (33.9)	421 (66.1)	
Urban	411 (36.2)	126 (30.7)	285 (69.3)	
Sub urban	86 (7.6)	27 (31.4)	59 (68.6)	
<i>Current living location</i>				0.048
Central zone	680 (60.0)	237 (34.9)	443 (65.1)	
North zone	237 (20.9)	62 (26.2)	175 (73.8)	
South zone	217 (19.1)	70 (32.3)	147 (67.7)	
<i>Current Residence type</i>				0.042
Rented	514 (45.3)	184 (35.8)	330 (64.2)	
Own	525 (46.3)	151 (28.8)	374 (71.2)	
Hostel/Mess	95 (8.4)	34 (35.8)	61 (64.2)	
<i>Regular religious practice</i>				0.064
No	328 (28.9)	120 (36.6)	208 (63.4)	
Yes	806 (71.1)	249 (30.9)	557 (69.1)	
<i>Tobacco user</i>				0.037
No	796 (70.2)	244 (30.7)	552 (69.3)	
Yes	338 (29.8)	125 (37.0)	213 (63.0)	
<i>Did you face physical illness in last one year</i>				0.006
No	650 (57.3)	233 (35.8)	417 (64.2)	
Yes	484 (42.7)	136 (28.1)	348 (71.9)	
<i>Morbidity</i>				0.943
No	859 (75.7)	280 (32.6)	579 (67.4)	
Yes	275 (24.3)	89 (32.4)	186 (67.6)	
<i>Political affiliation</i>				0.050
Ruling party	340 (30.0)	119 (35.0)	221 (65.0)	
Opposition	153 (13.5)	59 (38.6)	94 (61.4)	
Neutral	641 (56.5)	191 (29.8)	450 (70.2)	
<i>Do you think the COVID-19 vaccine will be effective among Bangladeshis</i>				<0.001
No	108 (9.5)	72 (66.7)	36 (33.3)	
Yes	367 (32.4)	43 (11.7)	324 (88.3)	
Skeptical	659 (58.1)	254 (38.5)	405 (61.5)	
<i>Which developers' vaccine would you prefer</i>				0.001
American	435 (38.4)	160 (36.8)	275 (63.2)	
British	372 (32.8)	102 (27.4)	270 (72.6)	
Chinese	82 (7.2)	21 (25.6)	61 (74.4)	
Russian	64 (5.6)	16 (25.0)	48 (75.0)	
Indian	39 (3.4)	8 (20.5)	31 (79.5)	
Others/no idea	142 (12.5)	62 (43.7)	80 (56.3)	
<i>Perceived likelihood of getting infected in the next 1 year</i>				<0.001
Very likely	388 (34.2)	141 (36.3)	247 (63.7)	
Somewhat likely	608 (53.6)	146 (24.0)	462 (76.0)	
Not likely	83 (7.3)	51 (61.4)	32 (38.6)	
Definitely not	55 (4.9)	31 (56.4)	24 (43.6)	
<i>Level of concern about getting infected in the next 1 year</i>				<0.001
Very concerned	226 (19.9)	30 (13.3)	196 (86.7)	
Concerned	290 (25.6)	53 (18.3)	237 (81.7)	
Slightly concerned	235 (20.7)	69 (29.4)	166 (70.6)	
Not concerned at all	383 (33.8)	217 (56.7)	166 (43.3)	

Table 2 Multiple logistic regression- predictors of vaccine hesitancy in study participants

Variables	Adjusted Odds Ratio	Standard Error	Confidence Interval	p-value
<i>Gender</i>				
Transgender	3.639	0.576	1.177-11.251	0.025
Female	0.706	0.139	0.537-0.928	0.013
Male	Reference			
<i>Age group</i>				
18-25	Reference			
26-40	1.208	0.179	0.851-1.715	0.290
41-60	0.808	0.238	0.508-1.285	0.368
≥ 61	1.053	0.434	0.450-2.465	0.905
<i>Marital status</i>				
Unmarried	Reference			
Married	1.485	0.175	1.047-2.106	0.027
Divorce/Widow	1.606	0.394	0.742-3.44	0.229
<i>Employment Status</i>				
Full-time employee	1.006	0.217	0.657-1.539	0.979
Part-time employee	0.914	0.315	0.439-1.693	0.775
Business	1.230	0.227	0.788-1.921	0.362
Unemployed	1.311	0.284	0.751-2.286	0.341
Student	0.606	0.238	0.379-0.966	0.035
Home maker	Reference			
<i>Monthly household income</i>				
<15,000	Reference			
15,000-30,000	0.790	0.185	0.550-1.136	0.203
≥ 30,000	1.181	0.185	0.822-1.696	0.368
<i>Current living location</i>				
Central zone	1.105	0.169	0.793-1.540	0.554
North zone	0.762	0.209	0.506-1.147	0.192
South zone	Reference			
<i>Current Residence type</i>				
Rented	0.962	0.235	0.607-1.527	0.871
Own	0.761	0.241	0.475-1.221	0.258
Hostel/Mess	Reference			
<i>Tobacco user</i>				
No	Reference			
Yes	1.333	0.138	1.018-1.745	0.037
<i>Did you face physical illness in last one year</i>				
No	1.486	0.138	1.134-1.949	0.004
Yes	Reference			
<i>Political affiliation</i>				
Ruling party	1.269	0.143	0.959-1.678	0.096
Opposition	1.479	0.187	1.025-2.134	0.037
Neutral	Reference			

<i>Do you think the COVID-19 vaccine will be effective among Bangladeshis</i>				
No	3.199	0.220	2.079-4.925	<0.001
Yes	0.212	0.182	0.149-0.303	<0.001
Skeptical	Reference			
<i>Which developers' vaccine would you prefer</i>				
American	0.744	0.197	0.506-1.094	0.133
British	0.484	0.205	0.324-0.725	<0.001
Chinese	0.444	0.304	0.245-0.807	0.008
Russian	0.428	0.335	0.222-0.825	0.011
Indian	0.332	0.431	0.143-0.774	0.011
No idea	Reference			
<i>Perceived likelihood of getting infected in the next 1 year</i>				
Very likely	Reference			
Somewhat likely	0.645	0.161	0.471-0.884	0.006
Not likely	1.875	0.268	1.109-3.172	0.019
Definitely not	1.099	0.307	0.602-2.007	0.758
<i>Level of concern about getting infected in the next 1 year</i>				
Very concerned	Reference			
Concerned	1.609	0.255	0.977-2.649	0.062
Slightly concerned	2.869	0.254	1.744-4.721	<0.001
Not concerned at all	7.450	0.228	4.768-11.643	<0.001

Figure legend:

Figure 1 Day-to-day fluctuation of COVID-19 vaccine wiliness and/or hesitancy among Bangladeshi